Bay­er’s projects with Twist, Evotec; Ab­b­Vie buys out Parkin­son’s drug­mak­er; A new drug dis­cov­ery non­prof­it in Toron­to

Bay­er teams up with Twist: The Ger­man drug­mak­er en­tered in­to a drug dis­cov­ery deal with Cal­i­for­nia biotech Twist Bio­science. Twist will use its syn­thet­ic an­ti­body li­braries to dis­cov­er an­ti­bod­ies against tar­gets se­lect­ed by Bay­er, which will have the op­tion to li­cense them. Twist is el­i­gi­ble for up to $188 mil­lion in up­front and mile­stones pay­ments as well as tiered roy­al­ties on po­ten­tial prod­uct sales. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER